GSK’s Fluarix Tetra wins European approval for expanded indication
Fluarix Tetra has been approved in Europe to include adults and now children from six months of age for the prevention of influenza disease caused by the two
Teva Pharmaceutical has announced the US Food and Drug Administration (FDA) approval for Ponlimsi (denosumab-adet) as a biosimilar to Prolia, alongside the acceptance of its biosimilar candidate applications for Xolair (omalizumab) by both the agency and the European Medicines Agency (EMA).
The programs will leverage CureVac’s RNActive prophylactic vaccine technology to develop mRNA-based vaccines designed to prevent influenza and malaria infection. These vaccines, which are flexible in their applications,
The approval is for Glatopa 40mg/mL as a fully-substitutable, AP-rated generic version of Teva Pharmaceutical Industries’ three times-a-week Copaxone 40mg/mL therapy (glatiramer acetate injection). Glatopa was approved by